Literature DB >> 6288076

Purification of a skeletal growth factor from human bone.

J R Farley, D J Baylink.   

Abstract

A skeletal growth factor was isolated and purified from demineralized human bone matrix. A dose of 6 micrograms/mL of the purified factor significantly increased the proliferation rate of embryonic chick bone cells in serum-free culture (292% of controls, p less than 0.0001) but had no effect on embryonic chick skin cells plated at the same initial density. The factor is sensitive to inactivation by trypsin and urea, but not by collagenase, 20% butanol, or 1% mercaptoethanol. It is also resistant to inactivation by heat (stable for 15 min at 75 degrees C) and extremes of pH (stable for 30 min at 4 degrees C from pH 2.5 to 10.0). Purification of the active factor by selective heat and acid precipitations, molecular sieve column chromatography, and preparative polyacrylamide gel electrophoresis provided a material that was homogeneous by the criteria of high-pressure liquid chromatography, polyacrylamide gel electrophoresis, and isoelectric focusing. The apparent molecular weight is 83 000. The purified factor increases bone cell proliferation at doses comparable to other mitogens: 0.3 microgram/mL (3.6 nM) significantly increases DNA synthesis to 231% of controls (p less than 0.001). The purified factor was also active on cultured embryonic chick bones, enhancing the growth rate of tibiae and femurs, as measured by increased dry weight (185% of controls, p less than 0.025) and [3H]proline incorporation (164% of control, p less than 0.001), respectively.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288076     DOI: 10.1021/bi00257a037

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  [Osteoinduction and -reparation].

Authors:  N R Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  1997-02

2.  The effect of bone cell stimulatory factors can be measured with thymidine incorporation only under specific conditions.

Authors:  J E Puzas; J S Brand
Journal:  Calcif Tissue Int       Date:  1986-08       Impact factor: 4.333

3.  Immunocytochemical localization of BGP in human bones in various developmental stages and pathological conditions.

Authors:  T Ohta; M Mori; K Ogawa; T Matsuyama; S Ishii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones.

Authors:  J Pfeilschifter; G R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Reactive endosteal bone formation.

Authors:  J Aoki; I Yamamoto; M Hino; N Kitamura; T Sone; H Itoh; K Torizuka
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

6.  Bone-derived factors active on bone cells.

Authors:  S Mohan; T Linkhart; J Farley; D Baylink
Journal:  Calcif Tissue Int       Date:  1984       Impact factor: 4.333

7.  Local bone growth factors.

Authors:  E Canalis
Journal:  Calcif Tissue Int       Date:  1984-12       Impact factor: 4.333

8.  Osteosclerosis associated with urinary tract malignancy may not be dependent upon bone metastases.

Authors:  T B Connor; B L Rosen; R Cranley; E McCrea; T K Gray
Journal:  Trans Am Clin Climatol Assoc       Date:  1983

9.  Identification of the noncollagenous proteins of bovine bone by two-dimensional gel electrophoresis.

Authors:  P D Delmas; R P Tracy; B L Riggs; K G Mann
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

10.  Effects of acetylsalicylic acid on intramuscular bone matrix implants and composite grafts in rats.

Authors:  L F Solheim; H Rönningen; E Barth; N Langeland
Journal:  Arch Orthop Trauma Surg       Date:  1987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.